tetano
Editor, Senior Moderator
Hematol Rep
. 2024 Sep 27;16(4):585-592.
doi: 10.3390/hematolrep16040057. Two Cases of Immune Thrombocytopenia (ITP) Related to Viral Vector Vaccination ChAdOx1-S (AstraZeneca) and a Good Response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy
Konstantina Salveridou[SUP] 1 2 [/SUP], Theodoros Tzamalis[SUP] 1 [/SUP], Maika Klaiber-Hakimi[SUP] 1 [/SUP], Sabine Haase[SUP] 1 [/SUP], Stefanie Gröpper[SUP] 1 [/SUP], Aristoteles Giagounidis[SUP] 1 [/SUP]
Affiliations
Background: In 2019, a new coronavirus disease emerged in Wuhan, China, known as SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, and caused an ongoing pandemic. Symptomatology of the syndrome is variable, with complications extending to hematopoiesis and hemostasis. Approximately a year after onset of the virus, four vaccination formulas became available to the public, based on a viral vector or mRNA technology. These vaccine formulas have been hampered with hematological complications, like vaccine-induced immune thrombotic thrombocytopenia (VITT) and vaccine-related ITP (immune thrombocytopenic purpura). ITP is a disease with autoimmune pathogenesis characterized by antibody production against platelets and an increased hemorrhagic risk. A decent number of cases have been referred to as possible adverse effects of COVID-19 vaccinations.
Case presentation: in this case report, we present two cases of newly diagnosed ITP after vaccination with ChAdOx1-S (AstraZeneca), with a good response to treatment with thrombopoietin-receptor agonists (TPO-RAs).
Discussion: we observed an absence of response after corticosteroids and IVIG therapy and a positive therapeutic outcome on TPO-RA.
Conclusions: in the ongoing pandemic, there is an urgent need to create therapeutic guidelines for vaccination-related clinical entities and to clarify indications for the vaccination of patients with pre-existing hematological diseases.
Keywords: COVID-19; ITP; TPO-RA; vaccine.
. 2024 Sep 27;16(4):585-592.
doi: 10.3390/hematolrep16040057. Two Cases of Immune Thrombocytopenia (ITP) Related to Viral Vector Vaccination ChAdOx1-S (AstraZeneca) and a Good Response after Thrombopoietin Receptor Agonist (TPO-RA) Therapy
Konstantina Salveridou[SUP] 1 2 [/SUP], Theodoros Tzamalis[SUP] 1 [/SUP], Maika Klaiber-Hakimi[SUP] 1 [/SUP], Sabine Haase[SUP] 1 [/SUP], Stefanie Gröpper[SUP] 1 [/SUP], Aristoteles Giagounidis[SUP] 1 [/SUP]
Affiliations
- PMID: 39449300
- PMCID: PMC11503447
- DOI: 10.3390/hematolrep16040057
Background: In 2019, a new coronavirus disease emerged in Wuhan, China, known as SARS-CoV-2, severe acute respiratory syndrome coronavirus 2, and caused an ongoing pandemic. Symptomatology of the syndrome is variable, with complications extending to hematopoiesis and hemostasis. Approximately a year after onset of the virus, four vaccination formulas became available to the public, based on a viral vector or mRNA technology. These vaccine formulas have been hampered with hematological complications, like vaccine-induced immune thrombotic thrombocytopenia (VITT) and vaccine-related ITP (immune thrombocytopenic purpura). ITP is a disease with autoimmune pathogenesis characterized by antibody production against platelets and an increased hemorrhagic risk. A decent number of cases have been referred to as possible adverse effects of COVID-19 vaccinations.
Case presentation: in this case report, we present two cases of newly diagnosed ITP after vaccination with ChAdOx1-S (AstraZeneca), with a good response to treatment with thrombopoietin-receptor agonists (TPO-RAs).
Discussion: we observed an absence of response after corticosteroids and IVIG therapy and a positive therapeutic outcome on TPO-RA.
Conclusions: in the ongoing pandemic, there is an urgent need to create therapeutic guidelines for vaccination-related clinical entities and to clarify indications for the vaccination of patients with pre-existing hematological diseases.
Keywords: COVID-19; ITP; TPO-RA; vaccine.